Nuo Therapeutics dismisses auditor Marcum, engages MaloneBailey; cites material weaknesses

Nuo Therapeutics, Inc.

Effective June 7, 2024, dismissed Marcum LLP as independent auditor; engaged MaloneBailey, LLP for FY 2024.
Marcum's reports for FY2023 and FY2022 included going-concern explanatory paragraphs.
Identified material weaknesses: insufficient accounting staff and lack of effective internal control over financial reporting.
No disagreements with Marcum on accounting principles or audit scope prior to dismissal.
Marcum's letter to SEC agreeing with disclosures filed as Exhibit 16.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.